Alisertib for extensive stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with small cell lung cancer that has spread (extensive stage).
- You have already had one platinum-based chemotherapy (like cisplatin or carboplatin) and one immunotherapy (PD-1/PD-L1 inhibitor).
- You may have had one additional treatment for SCLC, but no more than 2 total prior treatments.
- You have not been treated with a drug that targets the Aurora kinase (like alisertib) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests combining the targeted pill alectinib with chemotherapy before the main treatment for stage III ALK-positive lung cancer that can't be removed surgically. The goal is to see if this combo shrinks the tumor and improves outcomes.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.